BL
NBIX icon

BFSG LLC’s Neurocrine Biosciences NBIX Stock Holding History

BFSG LLC’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69K Sell
10
-4
-29% -$593 ﹤0.01% 705
2026
Q1 		$1.84K Hold
14
– – ﹤0.01% 677
2025
Q4 		$1.99K Hold
14
– – ﹤0.01% 649
2025
Q3 		$1.97K Sell
14
-3
-18% -$406 ﹤0.01% 642
2025
Q2 		$2.14K Hold
17
– – ﹤0.01% 606
2025
Q1 		$1.88K Buy
+17
New +$2.15K ﹤0.01% 609

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BFSG LLC's NBIX Position: Q2 2026 in Review

BFSG LLC reduced its Neurocrine Biosciences (NBIX) stake by 29% in Q2 2026, selling an estimated $593 and leaving 10 shares worth $1.69K. The position accounts for ﹤0.01% of the portfolio, ranked #705.

BFSG LLC first reported a position in NBIX in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.14K in Q2 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • BFSG LLC held 10 shares of Neurocrine Biosciences worth $1.69K as of Q2 2026.
  • BFSG LLC sold 4 Neurocrine Biosciences shares in Q2 2026, an estimated $593.
  • Neurocrine Biosciences made up ﹤0.01% of BFSG LLC's portfolio in Q2 2026, its #705 holding.
  • BFSG LLC first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 6 quarters since.
  • BFSG LLC's Neurocrine Biosciences position peaked at $2.14K in Q2 2025.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on BFSG LLC's 13F filing for Q2 2026, filed 20 Jul 2026.